Drug Profile
Interferon beta-1a extended release - Merck Serono
Latest Information Update: 23 Dec 2021
Price :
$50
*
At a glance
- Originator Merck Serono
- Class Antiasthmatics; Antineoplastics; Antivirals; Interferons; Proteins; Vascular disorder therapies
- Mechanism of Action Immunostimulants; Interferon beta stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Multiple sclerosis